Welcome to our dedicated page for Avivagen news (Ticker: VIVXF), a resource for investors and traders seeking the latest updates and insights on Avivagen stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avivagen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avivagen's position in the market.
Avivagen Inc. (TSXV:VIV) has approved the issuance of 577,500 stock options to its officers, directors, consultants, and employees. These options will vest over an eight-quarter period and are exercisable within five years at a strike price of $0.56. This issuance forms part of the total remuneration package for these individuals. Additionally, the grants are subject to approval from the TSX Venture Exchange. Avivagen focuses on products for livestock, companion animals, and human health, leveraging its OxC-beta™ technology to promote immune function and improve health economically.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced it will seek approval from the TSX Venture Exchange to extend the expiration date of warrants for 2,774,992 common shares at $0.90 per share, originally set to expire on March 31, 2021, to June 1, 2021. This extension is subject to approval by the exchange and will not alter any other terms of the warrants. Avivagen focuses on developing products that enhance immune function in livestock, companion animals, and humans, utilizing its OxC-beta™ technology as a non-antibiotic alternative in livestock feeds.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has announced the publication of a study in Poultry Science demonstrating the benefits of its OxC-betaTM Livestock product for broiler poultry. The research highlights significant improvements in growth performance and feed efficiency in birds supplemented with OxC-beta compared to control groups. Conducted in Canada and Scotland, the trials support OxC-beta as a non-antibiotic alternative for enhancing poultry health and performance. CEO Kym Anthony emphasizes the publication's validation of OxC-beta's commercial benefits, appealing to customers aiming to reduce antibiotic use.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announces its Q1 2021 financial results, reporting revenues of $261,987 and a comprehensive loss of $(1,266,300). Major milestones include securing a recurring order of 6 tonnes with Transformadora Agricola in Mexico and fulfilling orders in the Philippines, Taiwan, and Thailand. Subsequent achievements include a $7.5 million oversubscribed financing and expansion into Central and South America with Meyenberg International. The company emphasizes a bright outlook for 2021 with increased order volumes anticipated.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) announces its partnership with Meyenberg International Group to expand OxC-beta™ Livestock into Central and South America. Meyenberg, crucial to Avivagen's success in Mexico, will seek registrations in Costa Rica, Colombia, Peru, Uruguay, and Argentina. The five countries had a combined livestock feed consumption of approximately 40 million tonnes in 2020. OxC-beta™ Livestock offers a non-antibiotic solution to promote animal health and is already available in several countries, including the U.S. and Canada.
Mimi's Rock Corp. (TSXV:MIMI) and Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) have launched Dr. Tobias Beta Blend, a dietary supplement aimed at enhancing immune support and promoting skin and eye health. Available exclusively on Amazon and DrTobias.com, the product leverages Avivagen’s proprietary OxC-beta™ technology. Retailing at USD $29.97, this collaboration is expected to meet strong consumer demand, particularly in light of heightened awareness of immune health due to COVID-19.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) has secured a six-tonne order of OxC-beta™ Livestock from Transformadora Agricola de Alimentos S.A. de C.V in Mexico, starting April 2021 with monthly shipments of 500 kilograms. This is Avivagen's second significant order in Mexico within months, following a ten-tonne order in September 2020. CEO Kym Anthony expressed excitement over this new partnership and noted growing demand for their products in Mexico, where trials are ongoing with other prospective customers.
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) reported its fiscal 2020 results, showcasing significant growth across several metrics. Revenues reached $1,177,857, up from $977,451 in 2019, while the comprehensive loss narrowed to $(4,751,287) compared to $(4,836,420) in the previous year. The company secured regulatory approvals in critical markets, including Malaysia, Brazil, and support from COFCO Biotech for the Chinese market. Significant orders for OxC-beta™ Livestock were recorded in various countries, highlighting a strong market position. Total assets were reported at $2,176,142, against total liabilities of $6,943,752.
Avivagen (TSXV:VIV, OTCQB:VIVXF), a life sciences company offering natural alternatives to antibiotics, will present at the LD 500 investor conference on September 3rd at 12:40 PM PST. Kym Anthony, CEO, will showcase the company to a live audience. This event, running from September 1st to 4th, marks a significant milestone as it becomes fully accessible due to COVID-19 restrictions. The founder of LD Micro emphasizes the importance of adapting to the times while highlighting unique companies in the market.